A binary Xpovio catalyst is set for March.
ApexOnco Front Page
Recent articles
BeOne terminates a MUC1-targeting project.
The company hands its PD-L1 x VEGF bispecific back to ImmuneOnco.
Seven oncology approvals included nods for subcutaneous Rybrevant and Lunsumio.
PersonGen’s LV009 takes the industry tally of clinical-stage projects to 14.
Mocertatug rezetecan is starting its first western pivotal trials.
The holiday period included Genmab’s discontinuation of acasunlimab.
A deal with Jacobio is worth $100m up front.
